Concert Pharmaceuticals to Report Full Year 2016 Results on March 6, 2017, and Present at Upcoming Investor Conferences
02 Marzo 2017 - 6:00AM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced
that it will report its financial results for the year ended
December 31, 2016, on Monday, March 6, 2017, before the U.S.
financial markets open. The Company will host a conference call and
webcast at 8:30 a.m. EST to discuss 2016 financial results and
provide a business update. Individuals interested in participating
in the call should dial (855) 354-1855 (U.S. and Canada) or (484)
365-2865 (International).
In addition, the Company today announced that it will present a
corporate overview at the following upcoming investor
conferences:
- The 37th Annual Cowen and Company
Healthcare Conference on March 6, 2017 at 2:40 p.m. EST in Boston,
MA;
- The 29th Annual ROTH Conference on
March 14, 2017 at 11:30 a.m. PST in Dana Point, CA; and
- The Barclays Global Healthcare
Conference on March 16, 2017 at 9:30 a.m. EST in Miami, FL.
A live webcast of these presentations including the fourth
quarter financial results may be accessed in the Investors section
of the Company’s website at www.concertpharma.com. Please log on to
the Concert website approximately 15 minutes prior to the scheduled
webcast to ensure adequate time for any software downloads that may
be required. A replay of the fourth quarter financial results
webcast will be available on Concert’s website for three months. A
replay of the investor conference webcasts will be available on
Concert’s website for two weeks following each presentation.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical
company focused on applying its DCE Platform® (deuterated chemical
entity platform) to create novel medicines designed to address
unmet patient needs. The Company’s approach starts with approved
drugs in which deuterium substitution has the potential to enhance
clinical safety, tolerability or efficacy. Concert has a broad
pipeline of innovative medicines targeting pulmonary diseases,
including cystic fibrosis, autoimmune and inflammatory diseases and
central nervous systems (CNS) disorders. For more information
please visit www.concertpharma.com.
Concert Pharmaceuticals Inc., the CoNCERT
Pharmaceuticals Inc. logo and DCE Platform are registered
trademarks of Concert Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170302005160/en/
Concert Pharmaceuticals, Inc.Justine Koenigsberg,
781-674-5284ir@concertpharma.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Concert Pharmaceuticals Inc (NASDAQ): 0 recent articles
Más de Concert Pharmaceuticals, Inc. (MM) Artículos de Noticias